Conference Interview #10 of 12
Liz Meszaros, MDLinx
Iselin, New Jersey, United States | November 13-14, 2017
Preclinical testing on this new compound, which is comprised of an innate immune mimic synthetic molecule, has just been completed, and clinical testing is due to begin, he explained.
Genberg also highlighted concerns about colonization with fungi, which is often overlooked, and how this contributes to the toxicity of superbugs, and the incidence of hospital acquired infection. Overuse of antibiotics has allowed for the proliferation of fungal pathogens, such as Candida auris. According to Genberg, the colonization of both fungi and bacteria on medical devices synergize and work to increase the toxicity of hospital-acquired infections.